Campafungin A is a polyketide that
was recognized in the Candida albicans fitness test
due to its antiproliferative
and antihyphal activity. Its mode of action was hypothesized to involve
inhibition of a cAMP-dependent PKA pathway. The originally proposed
structure appeared to require a polyketide assembled in a somewhat
unusual fashion. However, structural characterization data were never
formally published. This background stimulated a reinvestigation in
which campafungin A and three closely related minor constituents were
purified from fermentations of a strain of the ascomycete fungus Plenodomus enteroleucus. Labeling studies, along with extensive
NMR analysis, enabled assignment of a revised structure consistent
with conventional polyketide synthetic machinery. The structure elucidation
of campafungin A and new analogues encountered in this study, designated
here as campafungins B, C, and D, is presented, along with a proposed
biosynthetic route. The antimicrobial spectrum was expanded to methicillin-resistant Staphylococcus aureus, Candida tropicalis, Candida glabrata, Cryptococcus neoformans, Aspergillus fumigatus, and Schizosaccharomyces
pombe, with MICs ranging as low as 4–8 μg mL–1 in C. neoformans. Mode-of-action
studies employing libraries of C. neoformans mutants
indicated that multiple pathways were affected, but mutants in PKA/cAMP
pathways were unaffected, indicating that the mode of action was distinct
from that observed in C. albicans.